Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer.

Détails

Ressource 1Télécharger: BIB_EFBCB71A50BF.P001.pdf (3840.99 [Ko])
Etat: Serval
Version: de l'auteur
ID Serval
serval:BIB_EFBCB71A50BF
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer.
Périodique
Oncoimmunology
Auteur(s)
Van't Hull E.F., Bron S., Henry L., Ifticene-Treboux A., Turrini R., Coukos G., Delaloye J.F., Doucey M.A.
ISSN
2162-4011 (Print)
Statut éditorial
Publié
Date de publication
2014
Volume
3
Pages
e29080
Langue
anglais
Notes
Publication types: JOURNAL ARTICLEPublication Status: epublish. pdf type: original research
Résumé
Bone marrow-derived endothelial progenitor cells (EPCs) infiltrate into sites of neovascularization in adult tissues and mature into functional blood endothelial cells (BECs) during a process called vasculogenesis. Human marrow-derived EPCs have recently been reported to display a mixed myeloid and lymphatic endothelial cell (LEC) phenotype during inflammation-induced angiogenesis; however, their role in cancer remains poorly understood. We report the in vitro differentiation of human cord blood CD133(+)CD34(+) progenitors into podoplanin(+) cells expressing both myeloid markers (CD11b, CD14) and the canonical LEC markers vascular endothelium growth factor receptor 3 (VEGFR-3), lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1), and prospero homeobox 1 (PROX-1). These podoplanin(+) cells displayed sprouting behavior comparable to that of LECs in vitro and a dual hemangiogenic and lymphangiogenic activity in vivo in an endothelial cell sprouting assay and corneal vascularization assay, respectively. Furthermore, these cells expressed vascular endothelium growth factor (VEGF) family members A, -C, and -D. Thus, bone-marrow derived EPCs stimulate hemangiogenesis and lymphangiogenesis through their ability to differentiate into LECs and to produce angiogenic factors. Importantly, plasma from patients with breast cancer induced differentiation of CD34(+) cord blood progenitors into hemangiogenic and lymphangiogenic CD11b(+) myeloid cells, whereas plasma from healthy women did not have this effect. Consistent with these findings, circulating CD11b(+) cells from breast cancer patients, but not from healthy women, displayed a similar dual angiogenic activity. Taken together, our results show that marrow-derived EPCs become hemangiogenic and lymphangiogenic upon exposure to cancer plasma. These newly identified functions of bone-marrow derived EPCs are expected to influence the diagnosis and treatment of breast cancer.
Pubmed
Web of science
Création de la notice
29/08/2014 14:44
Dernière modification de la notice
03/03/2018 22:35
Données d'usage